Drug Trial Radar · NCT07810062
A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative Women
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
990
Actual
Start
Aug 28, 2023
Primary completion
Jun 30, 2024
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Centre for Infectious Disease Research in ZambiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European and Developing Countries Clinical Trials Partnership (EDCTP); Medical Research Council, South Africa; University of Cape Town; Amsterdam Institute for Global Health and Development; Centre for the AIDS Programme of Research in South Africa; National Institute of Communicable Diseases - NICD
- First posted
- Sep 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 30 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A double blinded, Randomized, Placebo- controlled phase II trial to assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV- negative women
Conditions
- To Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS Monoclonal Antibodies in HIV-negative Women
Interventions
Broad band monoclonal antibodies named as CAP256V2LS and VRC07- 523LSBiological
HIV prevention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with any grade 3 or higher reactogenicity events within the first 3 days and adverse events after administration of CAP256V2LS in combination with VRC07-523LSTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Matero Clinical Research Site
Lusaka, Lusaka Province, Zambia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.